https://scholars.lib.ntu.edu.tw/handle/123456789/551262
標題: | Recent advances in the treatment of nasopharyngeal carcinoma | 作者: | Chang J.T.-C. JENQ-YUH KO RUEY-LONG HONG |
公開日期: | 2004 | 卷: | 103 | 期: | 7 | 起(迄)頁: | 496-510 | 來源出版物: | Journal of the Formosan Medical Association | 摘要: | The outcome of nasopharyngeal carcinoma (NPC) treatment has greatly improved as advances in imaging techniques increase the accuracy of tumor mapping. Radiotherapy remains a common treatment for early disease, while concurrent chemoradiotherapy is being increasingly accepted as the standard treatment for advanced disease. Intensity modulation radiotherapy (IMRT) delivers a more conformal radiation dose to the target area and may spare normal organs such as parotid gland for patients with early stage disease. IMRT in conjunction with concurrent chemotherapy offers excellent tumor control with fewer complications. These benefits suggest it will become the mainstay of radiotherapy treatment for NPC. Prevention of distant metastasis remains a crucial objective. The potential of induction chemotherapy to reduce distant metastasis has gained increased attention. Adjuvant chemotherapy has been unsuccessful due to poor tolerability. For metastasic NPC, cisplatin-based chemotherapy is effective but limited by cumulative toxicities. Newer drugs such gemcitabine and vinorelbine have been shown to be active in salvage therapy when cisplatin-containing combinations have failed. Due to their advantageous toxicity profiles, new drugs may replace cisplatin-based combinations as first-line treatment for metastasic NPC in the near future. Signal transduction manipulation is promising but has not been shown to be an essential therapy. Immunotherapy, such as mini-transplant, may offer the chance for durable control without long-term treatment, but its efficacy remains to be demonstrated. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-6344237620&partnerID=40&md5=acc41a312f1b39b3b8d1db9670faf249 https://scholars.lib.ntu.edu.tw/handle/123456789/551262 |
ISSN: | 0929-6646 | SDG/關鍵字: | antineoplastic agent; capecitabine; carboplatin; cetuximab; cisplatin; cyclophosphamide; docetaxel; doxorubicin; epirubicin; fluorouracil; folinic acid; gemcitabine; latent membrane protein 2; mitomycin C; navelbine; paclitaxel; UFT; unclassified drug; vincristine; virus protein; anemia; antineoplastic activity; blood toxicity; brachytherapy; cancer adjuvant therapy; cancer combination chemotherapy; cancer control; cancer immunotherapy; cancer recurrence; cancer resistance; cancer staging; clinical trial; diagnostic accuracy; diagnostic imaging; drug efficacy; drug eruption; drug hypersensitivity; drug tolerability; febrile neutropenia; granulocytopenia; hand foot syndrome; human; intensity modulated radiation therapy; leukopenia; long term care; maxilla resection; meta analysis; metastasis; mucosa inflammation; nasopharynx carcinoma; nausea; nephrotoxicity; neutropenia; ototoxicity; prognosis; radiation dose distribution; radiosurgery; review; salvage therapy; serodiagnosis; side effect; signal transduction; stomatitis; thrombocytopenia; treatment failure; treatment outcome; vomiting; Carcinoma; Humans; Nasopharyngeal Neoplasms; Neoplasm Staging; Prognosis |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。